Indazole compound, preparation method thereof and application of indazole compound in medicine
Patent Information
- Application Number
- CN202380030033.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-31
- Filing Date
- 2023-03-31
- Publication Date
- 2024-12-06
AI Technical Summary
Existing technologies are insufficient to effectively inhibit the pro-cancer transcriptional activity of TEAD proteins, leading to overactivation of YAP/TAZ in various cancers, resulting in chemotherapy resistance and cancer progression.
A class of indazole compounds has been developed to block the transcriptional activity of TEAD protein or its interaction with YAP/TAZ, and these compounds have been formulated into pharmaceutical compositions for the treatment and prevention of cancer.
It effectively inhibits the transcriptional activity of TEAD protein, reduces the cancer-promoting effect of YAP/TAZ in cancer cells, improves chemotherapy sensitivity, and slows cancer progression.
Smart Images

Figure CN119095828A_ABST
Abstract
Description
Indazole compounds, preparation methods thereof and their applications in medicine Technical Field
[0001] The present disclosure relates to the field of medicine and relates to an indazole compound, a method for preparing the same, and its use in medicine. Specifically, the present disclosure relates to an indazole compound represented by general formula (I), a method for preparing the same, a pharmaceutical composition containing the same, and its use as a TEAD inhibitor, particularly in the preparation of a medicament for treating and / or preventing cancer. Background Art
[0002] The Hippo signaling pathway, discovered in Drosophila and conserved in mammals, regulates the growth and development of the body or organs, cellular homeostasis, cell proliferation, and differentiation. The Hippo signaling pathway consists of a cascade signaling network composed of a series of kinases that regulate the entry and exit of downstream transcriptional coactivators, YAP / TAZ, into the cell nucleus through phosphorylation. When the Hippo pathway is inactivated, YAP / TAZ enter the cell nucleus and bind to the TEAD family of transcription factors, TEAD1-4, to regulate target gene transcription, thereby exerting a variety of biological behaviors. TEAD proteins are generally considered to be the main effector molecules mediating the growth-promoting and carcinogenic effects of YAP / TAZ.
[0003] Studies have shown that elevated expression or nuclear translocation of YAP and / or TAZ leads to overactivation in some tumors, including breast, non-small cell lung, ovarian, colorectal, pancreatic, prostate, gastric, esophageal, liver, and osteosarcoma. Hippo pathway gene mutations account for approximately 10% of all tumors. These include pleural mesothelioma, where YAP / TEAD overactivation is caused by upstream NF2 or LATS1 / 2 inactivation; YAP and / or TAZ amplification in cervical, ovarian, head and neck, lung, liver, breast, and prostate cancers; and YAP and TAZ gene fusions in epithelioid hemangioendothelioma and ependymoma.
[0004] YAP / TAZ activation also plays a role in resistance to chemotherapy or inhibitors of MAPK pathways such as EGFR, ALK, and RAF / MEK. Studies have shown that YAP / TAZ mediates primary or secondary resistance to these drugs by inhibiting apoptotic protein levels and upregulating the spindle assembly checkpoint.
[0005] Therefore, inhibiting the oncogenic transcriptional activity of YAP / TAZ-TEAD by inhibiting TEAD protein palmitoylation or inhibiting the YAP / TAZ-TEAD protein interaction is expected to become an effective treatment for the above-mentioned tumors.
[0006] Published related patent applications include WO2020097389A1, WO2020081572A1, WO2006052190A1, WO2019040380A1 and WO2020243415A2, etc.
[0007] Summary of the Invention
[0008] The purpose of the present disclosure is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
[0009] in:
[0010] Z is O or NH;
[0011] Ring A is an aryl group or a heteroaryl group;
[0012] R is an alkyl group or R w R x N, the alkyl group is optionally substituted with one or more substituents selected from the group consisting of a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a halogenated alkoxy group, a cyano group, an amino group, and a hydroxyl group;
[0013] R 1 Selected from hydrogen atoms, deuterium atoms, halogens, alkyl groups, R v O and R y R z N, the alkyl group is optionally substituted with one or more substituents selected from the group consisting of a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a halogenated alkoxy group, a cyano group, an amino group, and a hydroxyl group;
[0014] R w 、R x 、R y and R z are the same or different and are each independently selected from a hydrogen atom, a deuterium atom and an alkyl group, wherein the alkyl group is optionally substituted with one or more substituents selected from a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a haloalkoxy group, a cyano group, an amino group and a hydroxyl group;
[0015] R v is selected from alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from deuterium, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0016] R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, and a hydroxyalkyl group;
[0017] R 2 、R 3 and R 4 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n1 R n2 、-C(O)NR n3 R n4 、-C(O)R a1 、-C(O)OR a2 、-OR a3 、-S(O) t1 R a4 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0018] Each R 5 are the same or different and are each independently selected from a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0019] R n1 、R n2 、R n3 、R n4 、R n5 、R n6 、R n7 and R n8 is the same or different at each occurrence and is independently selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group;
[0020] or R n1 and R n2 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, R n3 and R n4 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, R n5 and R n6 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group or R n7 and R n8 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, wherein each of the heterocyclic groups is independently optionally substituted by one or more substituents selected from the group consisting of a deuterium atom, a halogen, an oxo group, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, a deuterated alkoxy group, a haloalkoxy group, a cyano group, an amino group, a nitro group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
[0021] R a1 、R a2 、R a3 、R a4 、R a5 、R a6 、R a7 and R a8 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, deuterium, alkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of deuterium, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
[0022] t1 is 0, 1, or 2;
[0023] t2 is 0, 1, or 2;
[0024] m is 0, 1, 2, 3, 4, 5 or 6;
[0025] n is 0, 1, or 2;
[0026] The condition is,
[0027] i) When R is R w R x When N and n is 1, Not for
[0028] ii) When R is methyl and n is 0, R 1 Not for
[0029] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R is R w R x N, R w and R x As defined in general formula (I).
[0030] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; preferably, ring A is a phenyl group or a 6-membered heteroaryl group; further preferably, ring A is selected from phenyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl; more preferably, ring A is phenyl or pyridyl; most preferably, ring A is phenyl.
[0031] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein each R 5 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, each R 5 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; further preferably, R 5 C 1-6 More preferably, R 5 It is trifluoromethyl.
[0032] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; preferably, m is 1.
[0033] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally selected from deuterium atoms, halogens, C 1-6 Alkoxy and C 1-6 Preferably, R is C 1-6 Alkyl or C 1-6 Deuterated alkyl; further preferably, R is C 1-6 More preferably, R is methyl.
[0034] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof:
[0035] in:
[0036] G 0 is a nitrogen atom or CR 5a ;
[0037] G 1 is a nitrogen atom or CR 5b ;
[0038] G 2 is a nitrogen atom or CR 5d ;
[0039] G 3 is a nitrogen atom or CR 5e ;
[0040] R 5a Selected from hydrogen atom, deuterium atom, F, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0041] R 5c Selected from hydrogen atom, deuterium atom, Cl, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8, cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0042] R 5b 、R 5d and R 5e are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0043] Among them, Z, R w 、R x 、R 1 、R 2 、R 3 、R 4 、R a 、R b 、R n5 、R n6 、R n7 、R n8 、R a5 、R a6 、R a7 、R a8 , t2 and n are as defined in the general formula (I).
[0044] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, R 2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, R 2 A hydrogen atom.
[0045] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 3 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, R 3 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, R 3 A hydrogen atom.
[0046] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, R 4 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, R 4 A hydrogen atom.
[0047] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R a Selected from hydrogen atoms, halogens and C 1-6 Alkyl; preferably, R a A hydrogen atom.
[0048] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; preferably, R b A hydrogen atom.
[0049] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein G 0 CR 5a , R 5a Selected from hydrogen atoms, F, Br, I, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, G 0 CR 5a , R 5a Selected from hydrogen atoms, F, Br, I, C 1-6 Alkyl and C 1-6 More preferably, G 0 For CH.
[0050] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein G 2 CR 5d , R 5d Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, G 2 CR 5d , R 5d Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, G 2 For CH.
[0051] In some embodiments of the present disclosure, the compound represented by general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof:
[0052] Among them, Z, R w 、R x 、R 1 , G 1 , G 3 、R 5c and n are as defined in general formula (II).
[0053] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein Z is O.
[0054] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from hydrogen atoms, C 1-6 Alkyl, R v O and R y R z N, C 1-6 The alkyl group is optionally selected from deuterium atoms, halogens, C 1-6 Alkoxy, C 1-6 is substituted by one or more substituents selected from the group consisting of haloalkoxy, cyano, amino and hydroxy, and R v 、R y and R z As defined in general formula (I); preferably, R 1 Selected from hydrogen atoms, C 1-6 Alkyl, R v O and R y R z N, R y and R z As defined in general formula (I); further preferably, R 1 Selected from hydrogen atoms, C 1-6 Alkyl, R v O and R y R z N, R y and R z are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Deuterated alkyl, R v C 1-6 Alkyl or C 1-6 Deuterated alkyl; more preferably, R 1is selected from hydrogen, isopropyl, methoxy, isopropyloxy, amino, methyl NH (ie, methylamino) and dimethyl N (ie, dimethylamino); most preferably, R 1 It is a methoxy group.
[0055] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R y and R z The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl, the C 1-6 The alkyl group is optionally selected from deuterium atoms, halogens, C 1-6 Alkoxy and C 1-6 is substituted by one or more substituents in a haloalkoxy group; preferably, R y and R z are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Deuterated alkyl; further preferably, R y and R z The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl; further preferably, R y and R z are the same or different and are each independently a hydrogen atom or a methyl group.
[0056] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R v C 1-6 Alkyl or 3 to 6-membered cycloalkyl, the C 1-6 The alkyl group or the 3 to 6-membered cycloalkyl group are each independently optionally selected from a deuterium atom, a halogen, a C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, cyano, amino, hydroxy and C 1-6 Preferably, R v C 1-6 Alkyl or 3 to 6-membered cycloalkyl, the C 1-6 The alkyl or 3 to 6 membered cycloalkyl groups are each independently optionally selected from deuterium atoms, halogens and C 1-6 is substituted by one or more substituents in the alkyl group; further preferably, R v Selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl and 3 to 6 membered cycloalkyl; More preferably, R v C 1-6Alkyl or C 1-6 Deuterated alkyl; more preferably, R v C 1-6 Alkyl; most preferably, R v is methyl or isopropyl.
[0057] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1; preferably, n is 0.
[0058] In some embodiments of the present disclosure, the compound represented by the general formula (II) or the general formula (III) or a pharmaceutically acceptable salt thereof, wherein G 1 CR 5b , R 5b Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, G 1 CR 5b , R 5b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, G 1 For CH.
[0059] In some embodiments of the present disclosure, the compound represented by the general formula (II) or the general formula (III) or a pharmaceutically acceptable salt thereof, wherein G 3 CR 5e , R 5e Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, G 3 CR 5e , R 5e Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 More preferably, G 3 For CH.
[0060] In some embodiments of the present disclosure, the compound represented by the general formula (II) or the general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 5e Selected from hydrogen atoms, F, Br, I, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, R 5e Selected from hydrogen atoms, F, Br, I, C 1-6 Alkyl and C 1-6 More preferably, R 5e For H.
[0061] In some embodiments of the present disclosure, the compound represented by the general formula (II) or the general formula (III) or a pharmaceutically acceptable salt thereof, wherein G 1 and G 3 All are CH.
[0062] In some embodiments of the present disclosure, the compound represented by the general formula (II) or the general formula (III) or a pharmaceutically acceptable salt thereof, wherein R 5c Selected from hydrogen atoms, Cl, Br, I, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyano, amino, C 1-6 Alkyl NH, (C 1-6 Alkyl)2N, C 1-6 Alkoxy, C 1-6 haloalkoxy and 3 to 8 membered cycloalkyl; preferably, R 5c Selected from hydrogen atoms, Cl, Br, I, C 1-6 Alkyl and C 1-6 Haloalkyl; further preferably, R 5c A hydrogen atom or C 1-6 More preferably, R 5c is a hydrogen atom or a trifluoromethyl group.
[0063] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R w A hydrogen atom or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally selected from deuterium atoms, halogens, C1-6 Alkoxy and C 1-6 is substituted by one or more substituents in a haloalkoxy group; preferably, R w Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Deuterated alkyl; further preferably, R w A hydrogen atom or C 1-6 Alkyl; More preferably, R w is a hydrogen atom or a methyl group.
[0064] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R x A hydrogen atom or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally selected from deuterium atoms, halogens, C 1-6 Alkoxy and C 1-6 is substituted by one or more substituents in a haloalkoxy group; preferably, R x Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Deuterated alkyl; further preferably, R x A hydrogen atom or C 1-6 Alkyl; further preferably, R x C 1-6 Alkyl; More preferably, R x It is a methyl group.
[0065] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R x A hydrogen atom.
[0066] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R n1 、R n2 、R n3 、R n4 、R n5 、R n6 、R n7 and R n8 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 preferably, R n1 、R n2 、R n3 、R n4 、R n5 、R n6 、R n7and R n8 is the same or different at each occurrence and is independently a hydrogen atom or a C 1-6 alkyl.
[0067] In some embodiments of the present disclosure, the compound represented by formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt thereof, wherein R a1 、R a2 、R a3 、R a4 、R a5 、R a6 、R a7 and R a8 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 preferably, R a1 、 R a2 、R a3 、R a4 、R a5 、R a6 、R a7 and R a8 is the same or different at each occurrence and is independently C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0068] In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein t1 is 0 or 2; preferably, t1 is 2.
[0069] In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or general formula (III) or a pharmaceutically acceptable salt thereof, wherein t2 is 0 or 2; preferably, t2 is 2.
[0070] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein Z is O or NH; R w Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Deuterated alkyl; R x Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Deuterated alkyl; R 1 Selected from hydrogen atoms, C 1-6 Alkyl, R v O and R y R z N, R y and R z are the same or different and are each independently selected from hydrogen atom, C1-6 Alkyl and C 1-6 Deuterated alkyl, R v C 1-6 Alkyl or C 1-6 Deuterated alkyl; R 2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; R 3 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; R 4 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; R a Selected from hydrogen atoms, halogens and C 1-6 Alkyl; R b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; n is 0 or 1; G 0 CR 5a , R 5a Selected from hydrogen atoms, F, Br, I, C 1-6 Alkyl and C 1-6 Haloalkyl; G 2 CR 5d , R 5d Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; G 1 CR 5b , R 5b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; G 3 CR 5e , R 5e Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; and R 5c Selected from hydrogen atoms, Cl, Br, I, C 1-6 Alkyl and C 1-6 Halogenated alkyl.
[0071] In some embodiments of the present disclosure, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof, wherein Z is O; R w A hydrogen atom or C 1-6 Alkyl; R x C 1-6 Alkyl; R 1 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy and R y R z N, Ry and R z The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl; G 1 CR 5b , R 5b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; G 3 CR 5e , R 5e Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; R 5c A hydrogen atom or C 1-6 haloalkyl; and n is 0 or 1.
[0072] In some embodiments of the present disclosure, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof, wherein Z is O; R w A hydrogen atom or C 1-6 Alkyl; R x A hydrogen atom or C 1-6 Alkyl; R 1 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy and R y R z N, R y and R z The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl; G 1 CR 5b , R 5b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; G 3 CR 5e , R 5e Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; R 5c A hydrogen atom or C 1-6 haloalkyl; and n is 0 or 1.
[0073] Table A Typical compounds of the present disclosure include, but are not limited to:
[0074] Another aspect of the present disclosure relates to a compound represented by general formula (IIa) or a salt thereof:
[0075] in:
[0076] R L is an amino protecting group; preferably, R L For PMB;
[0077] R x , Z, R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n are as defined in general formula (II).
[0078] Another aspect of the present disclosure relates to a compound represented by general formula (IIIa) or a salt thereof:
[0079] in:
[0080] R L is an amino protecting group; preferably, R L For PMB;
[0081] R x , Z, R 1 、R 5c , G 1 , G 3 and n are as defined in general formula (III).
[0082] Another aspect of the present disclosure relates to a compound represented by general formula (IIA) or a salt thereof:
[0083] in:
[0084] R N is halogen; preferably, R N is Cl;
[0085] R 5c Selected from deuterium atoms, Cl, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8, cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0086] Z, R 1 、R 2 、R 3 、R 4 、R a 、R b , G 0 , G 1 , G 2 , G 3 、R n5 、R n6 、R n7 、R n8 、R a5 、R a6 、R a7 、R a8 , t2 and n are as defined in the general formula (II).
[0087] Another aspect of the present disclosure relates to a compound represented by general formula (IIIA) or a salt thereof:
[0088] in:
[0089] R N is halogen; preferably, R N is Cl;
[0090] Z, R 1 、R 5c , G 1 , G 3 and n are as defined in formula (IIA).
[0091] Table B Typical intermediate compounds disclosed herein include, but are not limited to:
[0092] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0093] The compound represented by general formula (IIa) or its salt is subjected to a deprotection reaction to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt;
[0094] in:
[0095] R L is an amino protecting group; preferably, R L For PMB;
[0096] R w is a hydrogen atom;
[0097] R x , Z, R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n are as defined in general formula (II).
[0098] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a salt thereof, the method comprising the following steps:
[0099] The compound represented by general formula (IIIa) or its salt is subjected to a deprotection reaction to obtain the compound represented by general formula (III) or its pharmaceutically acceptable salt;
[0100] in:
[0101] R L is an amino protecting group; preferably, R L For PMB;
[0102] R w is a hydrogen atom;
[0103] R x , Z, R 1 、R 5c , G 1 , G 3 and n are as defined in general formula (III).
[0104] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0105] The compound represented by general formula (IIA) or its salt undergoes a sulfonylation reaction with the compound represented by general formula (IIB) or its salt to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt;
[0106] in:
[0107] R Nis halogen; preferably, R N is Cl;
[0108] Z, R x 、R w 、R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n are as defined in general formula (II).
[0109] Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0110] The compound represented by general formula (IIIA) or its salt undergoes a sulfonylation reaction with the compound represented by general formula (IIB) or its salt to obtain the compound represented by general formula (III) or its pharmaceutically acceptable salt;
[0111] in:
[0112] R N is halogen; preferably, R N is Cl;
[0113] Z, R x 、R w 、R 1 、R 5c , G 1 , G 3 and n are as defined in general formula (III).
[0114] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III) or Table A of the present disclosure, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0115] The present disclosure further relates to the use of a compound represented by Formula (I), Formula (II), Formula (III) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a TEAD inhibitor drug.
[0116] The present disclosure further relates to the use of a compound represented by Formula (I), Formula (II), Formula (III) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a drug for inhibiting YAP / TAZ-TEAD transcriptional activity.
[0117] The present disclosure further relates to the use of a compound represented by Formula (I), Formula (II), Formula (III) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by YAP / TAZ-TEAD interaction.
[0118] The present disclosure further relates to the use of a compound of formula (I), formula (II), formula (III) or shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same in the preparation of a medicament for treating and / or preventing cancer, fibrosis, polycystic kidney disease and cardiovascular disease; the fibrosis is preferably liver fibrosis; the cancer is preferably selected from mesothelioma, schwannoma, leukemia, lymphoma, macroglobulinemia, heavy chain disease, sarcoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, cystadenocarcinoma, medullary carcinoma, bronchial carcinoma, liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, endometrial cancer, testicular cancer, lung cancer, bladder cancer, glioma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioma, acoustic neuroma, schwannoma, neurofibroma, retinoblastoma, melanoma, skin cancer, kidney cancer, nasopharyngeal cancer, stomach cancer, esophageal cancer, head and neck cancer, colorectal cancer, small intestine cancer, gallbladder cancer, pediatric cancer, urothelial carcinoma, ureteral cancer, thyroid cancer, bone tumor, neuroblastoma, brain tumor, ependymoma and myeloma.
[0119] The present disclosure further relates to a method for inhibiting YAP / TAZ-TEAD transcriptional activity, comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by Formula (I), Formula (II), Formula (III) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0120] The present disclosure further relates to a method for inhibiting TEAD, comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by Formula (I), Formula (II), Formula (III) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0121] The present disclosure further relates to a method for treating and / or preventing a disease or condition mediated by YAP / TAZ-TEAD interaction, comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by Formula (I), Formula (II), Formula (III), or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0122] The present disclosure further relates to a method for treating and / or preventing cancer, fibrosis, polycystic kidney disease and cardiovascular disease; the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), formula (II), formula (III) or shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same; the fibrosis is preferably liver fibrosis; the cancer is preferably selected from mesothelioma, schwannoma, leukemia, lymphoma, macroglobulinemia, heavy chain disease, sarcoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, sweat gland cancer, sebaceous gland cancer, papillary carcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, endometrial cancer, testicular cancer, lung cancer, bladder cancer, glioma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioma, acoustic neuroma, schwannoma, neurofibroma, retinoblastoma, melanoma, skin cancer, kidney cancer, nasopharyngeal cancer, stomach cancer, esophageal cancer, head and neck cancer, colorectal cancer, small intestine cancer, gallbladder cancer, pediatric cancer, urothelial carcinoma, ureteral cancer, thyroid cancer, osteoma, neuroblastoma, brain tumor, ependymoma and myeloma.
[0123] The present disclosure further relates to a compound represented by formula (I), formula (II), formula (III) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use as a medicament.
[0124] The present disclosure further relates to a compound represented by Formula (I), Formula (II), Formula (III) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a TEAD inhibitor.
[0125] The present disclosure further relates to a compound represented by formula (I), formula (II), formula (III) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in inhibiting YAP / TAZ-TEAD transcriptional activity.
[0126] The present disclosure further relates to a compound represented by Formula (I), Formula (II), Formula (III) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in treating and / or preventing diseases or conditions mediated by YAP / TAZ-TEAD interaction.
[0127] The present disclosure further relates to a compound of formula (I), formula (II), formula (III) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for treating and / or preventing cancer, fibrosis, polycystic kidney disease and cardiovascular disease; the fibrosis is preferably liver fibrosis; the cancer is preferably selected from mesothelioma, schwannoma, leukemia, lymphoma, macroglobulinemia, heavy chain disease, sarcoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, Liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, endometrial cancer, testicular cancer, lung cancer, bladder cancer, glioma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioma, acoustic neuroma, schwannoma, neurofibroma, retinoblastoma, melanoma, skin cancer, kidney cancer, nasopharyngeal cancer, stomach cancer, esophageal cancer, head and neck cancer, colorectal cancer, small intestine cancer, gallbladder cancer, pediatric cancer, urothelial carcinoma, ureteral cancer, thyroid cancer, bone tumor, neuroblastoma, brain tumor, ependymoma and myeloma.
[0128] The diseases or conditions mediated by the YAP / TAZ-TEAD interaction described in the present disclosure are preferably selected from cancer, fibrosis, polycystic kidney disease and cardiovascular disease; the fibrosis is preferably liver fibrosis; the cancer is preferably selected from mesothelioma, schwannoma, leukemia, lymphoma, macroglobulinemia, heavy chain disease, sarcoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, hepatocellular carcinoma, bile duct carcinoma, choriocarcinoma, spermatogonia, tumors, embryonal carcinoma, Wilms' tumor, cervical cancer, endometrial cancer, testicular cancer, lung cancer, bladder cancer, glioma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioma, acoustic neuroma, schwannoma, neurofibroma, retinoblastoma, melanoma, skin cancer, kidney cancer, nasopharyngeal cancer, stomach cancer, esophageal cancer, head and neck cancer, colorectal cancer, small intestine cancer, gallbladder cancer, pediatric cancer, urothelial carcinoma, ureteral cancer, thyroid cancer, bone tumor, neuroblastoma, brain tumor, ependymoma, and myeloma.
[0129] The mesothelioma described in the present disclosure is preferably pleural mesothelioma; the sarcoma is preferably soft tissue sarcoma or osteosarcoma; the ovarian cancer is preferably ovarian serous adenocarcinoma; the liver cancer is preferably hepatocellular carcinoma; the endometrial cancer is preferably endometrial adenosquamous carcinoma; the lung cancer is preferably non-small cell lung cancer; the glioma is preferably glioblastoma; the hemangioma is preferably hemangioblastoma or epithelioid hemangioendothelioma; the neurothema is preferably malignant peripheral nerve sheath tumor; the gastric cancer is preferably gastric adenocarcinoma; the esophageal cancer is preferably esophageal adenocarcinoma; and the brain tumor is preferably meningioma.
[0130] The active compound can be prepared into a form suitable for administration by any appropriate route, and the compositions of the present disclosure can be prepared using one or more pharmaceutically acceptable carriers by conventional methods. Thus, the active compound of the present disclosure can be formulated into various dosage forms for oral administration, injection (e.g., intravenous, intramuscular or subcutaneous), inhalation or insufflation. The compounds of the present disclosure can also be formulated into dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges or syrups.
[0131] As a general guide, the active compound is preferably in a unit dosage form, or in a form that a patient can self-administer as a single dose. A unit dosage form of a compound or composition of the present disclosure may be a tablet, capsule, cachet, bottled solution, powder, granule, lozenge, suppository, reconstituted powder, or liquid formulation. Suitable unit dosage forms may range from 0.1 to 1000 mg.
[0132] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.
[0133] Tablets contain the active ingredient in admixture with nontoxic, pharmaceutically acceptable excipients suitable for tablet preparation. These excipients may include inert excipients, granulating agents, disintegrants, binders, and lubricants. Tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained-release effect over a longer period of time.
[0134] Oral formulations may also be provided in soft gelatin capsules wherein the active ingredient is mixed with an inert solid diluent or with a water-soluble carrier or oil-soluble vehicle.
[0135] Aqueous suspensions contain the active substance in admixture with excipients suitable for the preparation of aqueous suspensions. Such excipients are suspending agents, dispersing agents, or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents.
[0136] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil or mineral oil. The oil suspension may contain a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding antioxidants.
[0137] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweeteners, flavorings, preservatives, and antioxidants. Such formulations may also contain demulcents, preservatives, colorants, and antioxidants.
[0138] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous solutions. Acceptable vehicles or solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. Sterile injectable formulations may be sterile injectable oil-in-water microemulsions in which the active ingredient is dissolved in an oil phase. The injectable solution or microemulsion may be administered into the patient's bloodstream via local, bolus injection. Alternatively, the solution or microemulsion may be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain this constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous pump.
[0139] Pharmaceutical compositions of the present disclosure may be in the form of sterile water for injection or oil suspensions for intramuscular and subcutaneous administration. The suspensions may be prepared using suitable dispersants or wetting agents and suspending agents as described above according to known techniques. Sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral, nontoxic diluents or solvents. In addition, sterile fixed oils may be conveniently used as solvents or suspension media. For this purpose, any blended fixed oil may be used. In addition, fatty acids may also be used to prepare injections.
[0140] The disclosed compounds can be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.
[0141] The compounds of the present disclosure can be administered by preparing water-suspended dispersible powders and granules by adding water. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersing or wetting agent, a suspending agent, or one or more preservatives.
[0142] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the optimal treatment method such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.
[0143] Terminology
[0144] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0145] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., C 1-20 The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C 1-12 alkyl), more preferably an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6 Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0146] The term "alkylene" refers to a divalent alkyl group, wherein alkyl is as defined above, having from 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkylene group is preferably an alkylene group having 1 to 12 carbon atoms (i.e., C 1-12alkylene), more preferably an alkylene group having 1 to 6 carbon atoms (i.e., C 1-6 Alkylene). Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylene can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment. The substituents are preferably selected from one or more of D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0147] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkenyl). Non-limiting examples include: ethenyl, propenyl, isopropenyl, butenyl, etc. Alkenyl can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0148] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment, and the substituent is preferably selected from one or more of D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0149] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups may be substituted or unsubstituted. When substituted, they may be substituted at any available point of attachment, with the substituent preferably being selected from one or more of a D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0150] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., a monocyclic cycloalkyl) or a polycyclic ring system (i.e., a polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered cycloalkyl). The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e., a 3- to 12-membered cycloalkyl group), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e., a 3- to 8-membered cycloalkyl group), or preferably a cycloalkyl group having 3 to 6 ring atoms (i.e., a 3- to 6-membered cycloalkyl group).
[0151] Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl.
[0152] The polycyclic cycloalkyl group includes: spirocycloalkyl group, fused cycloalkyl group and bridged cycloalkyl group.
[0153] The term "spiroalkyl" refers to a polycyclic ring system having a common carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds within the ring, or one or more heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized to form nitrogen oxides; the sulfur may be optionally oxoed to form sulfoxides or sulfones, but does not include -OO-, -OS- or -SS-), provided that it contains at least one all-carbon ring and the point of attachment is on the all-carbon ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroalkyl). The spiroalkyl preferably has 6 to 14 ring atoms (i.e., a 6- to 14-membered spiroalkyl), and more preferably has 7 to 10 ring atoms (i.e., a 7- to 10-membered spiroalkyl). The spirocycloalkyl group includes a monospirocycloalkyl group and a polyspirocycloalkyl group (such as a bispirocycloalkyl group, etc.), preferably a monospirocycloalkyl group or a bispirocycloalkyl group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered monospirocycloalkyl group. Non-limiting examples include:
[0154] Its connection point can be at any position;
[0155] wait.
[0156] The term "fused cycloalkyl" refers to a polycyclic ring system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more heterocyclyls, aryls, or heteroaryls, wherein the point of attachment is on the monocyclic cycloalkyl, which may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused cycloalkyl). The fused cycloalkyl is preferably a fused cycloalkyl having 6 to 14 ring atoms (i.e., a 6- to 14-membered fused cycloalkyl), more preferably a fused cycloalkyl having 7 to 10 ring atoms (i.e., a 7- to 10-membered fused cycloalkyl). The fused cycloalkyl group includes bicyclic fused cycloalkyl groups and polycyclic fused cycloalkyl groups (such as tricyclic fused cycloalkyl groups, tetracyclic fused cycloalkyl groups, etc.), preferably bicyclic fused cycloalkyl groups or tricyclic fused cycloalkyl groups, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered bicyclic fused cycloalkyl groups. Non-limiting examples include: Its connection point can be at any position; wait.
[0157] The term "bridged cycloalkyl" refers to a full carbon polycyclic ring system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., a 5 to 20-membered bridged cycloalkyl). The bridged cycloalkyl preferably has a bridged cycloalkyl of 6 to 14 carbon atoms (i.e., a 6 to 14-membered bridged cycloalkyl), more preferably a bridged cycloalkyl of 7 to 10 carbon atoms (i.e., a 7 to 10-membered bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (e.g., tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl. Non-limiting examples include:
[0158] Its connection point can be at any position.
[0159] The cycloalkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0160] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl) containing at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-) in the ring, and having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl). The heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e., a 3- to 12-membered heterocyclic group); further preferably a heterocyclic group having 3 to 8 ring atoms (i.e., a 3- to 8-membered heterocyclic group); more preferably a heterocyclic group having 3 to 6 ring atoms (i.e., a 3- to 6-membered heterocyclic group) or preferably a heterocyclic group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heterocyclic group).
[0161] Non-limiting examples of the monocyclic heterocyclic group include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and homopiperazinyl.
[0162] The polycyclic heterocyclic group includes a spiro heterocyclic group, a fused heterocyclic group and a bridged heterocyclic group.
[0163] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS- or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl). The spiro heterocyclic radical preferably has a spiro heterocyclic radical (i.e., a 6 to 14 yuan spiro heterocyclic radical) of 6 to 14 ring atoms, more preferably a spiro heterocyclic radical (i.e., a 7 to 10 yuan spiro heterocyclic radical) with 7 to 10 ring atoms. The spiro heterocyclic radical includes monospiro heterocyclic radical and polyspiro heterocyclic radical (such as dispiro heterocyclic radical etc.), preferably monospiro heterocyclic radical or dispiro heterocyclic radical, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan monospiro heterocyclic radical. Non-limiting examples include:
[0164] wait.
[0165] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two adjacent atoms between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more cycloalkyl, aryl, or heteroaryl groups, wherein the point of attachment is on the monocyclic heterocyclyl, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl). The fused heterocyclic radical preferably has a fused heterocyclic radical of 6 to 14 ring atoms (i.e., a 6 to 14-membered fused heterocyclic radical), more preferably a fused heterocyclic radical of 7 to 10 ring atoms (i.e., a 7 to 10-membered fused heterocyclic radical). The fused heterocyclic radical includes bicyclic and polycyclic fused heterocyclic radicals (such as tricyclic fused heterocyclic radicals, tetracyclic fused heterocyclic radicals, etc.), preferably bicyclic fused heterocyclic radicals or tricyclic fused heterocyclic radicals, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused heterocyclic radicals. Non-limiting examples include:
[0166] wait.
[0167] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered bridged heterocyclic group). The bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e., a 6- to 14-membered bridged heterocyclic group), and more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e., a 7- to 10-membered bridged heterocyclic group). According to the number of constituent rings, heterocyclic groups can be divided into bicyclic bridged heterocyclic groups and polycyclic bridged heterocyclic groups (such as tricyclic bridged heterocyclic groups, tetracyclic bridged heterocyclic groups, etc.), preferably bicyclic bridged heterocyclic groups or tricyclic bridged heterocyclic groups. Non-limiting examples include: wait.
[0168] The heterocyclic group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment. The substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclic group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group.
[0169] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group is preferably an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group), more preferably an aromatic group having 8 to 10 ring atoms (i.e., an 8- to 10-membered polycyclic aromatic group). The monocyclic aromatic group is, for example, a phenyl group. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused to one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused to one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:
[0170] wait.
[0171] The aryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0172] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl), more preferably a heteroaryl having 5 or 6 ring atoms (i.e., a 5- or 6-membered monocyclic heteroaryl), or preferably a heteroaryl having 8 to 10 ring atoms (i.e., an 8- to 10-membered polycyclic heteroaryl).
[0173] The monocyclic heteroaryl groups include, but are not limited to, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, etc.
[0174] The polycyclic heteroaryl groups include, but are not limited to, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, benzofuranyl, quinazolinyl, carbazolyl, pyrrolotriazinyl, 5,6,7,8-tetrahydro-triazolopyrazinyl, imidazopyridazinyl and [1,2,4]triazolo[1,5-a]pyridinyl. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused with one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused with one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:
[0175] wait.
[0176] The heteroaryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0177] The term "amino protecting group" refers to a group that is easily removed and introduced onto an amino group in order to keep the amino group unchanged when other parts of the molecule react. Non-limiting examples include: (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methoxycarbonyl, ethoxycarbonyl, phthaloyl (Pht), p-toluenesulfonyl (Tos), trifluoroacetyl (Tfa), trityl (Trt), 2,4-dimethoxybenzyl (DMB), acetyl, benzyl, allyl, 4-methoxybenzyl (PMB), etc., preferably PMB.
[0178] The term "hydroxy protecting group" refers to a group that is introduced on a hydroxy group and is easily removed, and is used to block or protect the hydroxy group while reacting on other functional groups of the compound. Non-limiting examples include trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, etc.
[0179] The term "cycloalkyloxy" refers to a cycloalkyl-O- group in which cycloalkyl is as defined above.
[0180] The term "heterocyclyloxy" refers to a heterocyclyl-O- group in which heterocyclyl is as defined above.
[0181] The term "aryloxy" refers to an aryl-O- group in which the aryl group is as defined above.
[0182] The term "heteroaryloxy" refers to a heteroaryl-O- group in which heteroaryl is as defined above.
[0183] The term "alkylthio" refers to an alkyl-S- group in which alkyl is as defined above.
[0184] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0185] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0186] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0187] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0188] The term "methylidene" refers to =CH2.
[0189] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0190] The term "hydroxy" refers to -OH.
[0191] The term "mercapto" refers to -SH.
[0192] The term "amino" refers to -NH2.
[0193] The term "cyano" refers to -CN.
[0194] The term "nitro" refers to -NO2.
[0195] The term "oxo" or "oxo" refers to "=0".
[0196] The term "carbonyl" refers to C=O.
[0197] The term "carboxy" refers to -C(O)OH.
[0198] Ms is methanesulfonyl.
[0199] The term "carboxylate" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O-, or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.
[0200] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers having identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). The substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), by forming a diastereomeric salt with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art to obtain the pure isomer. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.
[0201] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations.
[0202] The compounds of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to a structural isomer that exists in equilibrium and is easily converted from one isomeric form to another. It includes all possible tautomers, i.e., existing in the form of a single isomer or in the form of a mixture of any proportions of the tautomers. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactim, etc. Examples of lactam-lactim equilibrium are shown below:
[0203] For example, when referring to pyrazolyl, it is understood to include either of the following two structures or a mixture of two tautomers:
[0204] All tautomeric forms are within the scope of the present disclosure, and the naming of compounds does not exclude any tautomer.
[0205] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p、 33 p、 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium.
[0206] Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed by the present disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced with a deuterium atom, where the deuterium replacement can be partial or complete. Partial deuterium replacement refers to the replacement of at least one hydrogen atom with at least one deuterium atom.
[0207] In the disclosed compounds, when a position is specifically designated as "deuterium" or "D," the position is understood to have an abundance of deuterium at least 1000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 2000 times greater than the natural abundance of deuterium (i.e., at least 30% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3000 times greater than the natural abundance of deuterium (i.e., at least 45% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3340 times greater than the natural abundance of deuterium (i.e., at least 50.1% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3500 times greater than the natural abundance of deuterium (i.e., at least 52.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4000 times greater than the natural abundance of deuterium (i.e., at least 60% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4500 times greater than the natural abundance of deuterium (i.e., at least 67.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5000 times greater than the natural abundance of deuterium (i.e., at least 75% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5500 times greater than the natural abundance of deuterium (i.e., at least 82.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6000 times greater than the natural abundance of deuterium (i.e., at least 90% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6333.3 times greater than the natural abundance of deuterium (i.e., at least 95% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6466.7 times greater than the natural abundance of deuterium (i.e., at least 97% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6600 times greater than the natural abundance of deuterium (i.e., at least 99% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (ie, at least 99.5% deuterium incorporation).
[0208] "Optional" or "optionally" means that the event or circumstances described subsequently may but need not occur, and includes both situations in which the event or circumstances occur and do not occur. For example, "alkyl optionally substituted with halogen or cyano" includes both situations in which the alkyl is substituted with halogen or cyano and situations in which the alkyl is not substituted with halogen and cyano.
[0209] "Substitution" or "substituted" means that one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, in a group are independently replaced by a corresponding number of substituents. Those skilled in the art can determine (by experiment or theory) whether substitution is possible or not without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated bond (such as an alkene).
[0210] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or pharmaceutically acceptable salts thereof, and other chemical components, as well as other components such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.
[0211] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective for use in mammals and possess the desired biological activity. They can be prepared during the final isolation and purification of the compound, or separately by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids and organic acids.
[0212] With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to an amount of the drug or agent sufficient to achieve, or at least partially achieve, the desired effect. The determination of a therapeutically effective amount varies from person to person, depending on the age and general condition of the recipient, as well as the specific active substance. The appropriate therapeutically effective amount in each individual case can be determined by those skilled in the art through routine experimentation.
[0213] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.
[0214] As used herein, the singular form "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.
[0215] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, numbers are generally given for illustration purposes only and are not limiting.
[0216] Synthesis method of the disclosed compound
[0217] In order to achieve the purpose of this disclosure, the present disclosure adopts the following technical solutions:
[0218] Option 1
[0219] The method for preparing the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0220] The compound represented by general formula (IIa) or its salt is subjected to a deprotection reaction under acidic conditions to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt;
[0221] in:
[0222] R L is an amino protecting group; preferably, R L For PMB;
[0223] R w is a hydrogen atom;
[0224] R x , Z, R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n are as defined in general formula (II).
[0225] Option 2
[0226] The method for preparing the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0227] The compound represented by general formula (IIIa) or its salt is subjected to a deprotection reaction under acidic conditions to obtain the compound represented by general formula (III) or its pharmaceutically acceptable salt;
[0228] in:
[0229] R L is an amino protecting group; preferably, R L For PMB;
[0230] R w is a hydrogen atom;
[0231] R x , Z, R 1 、R 5c , G 1 , G3 and n are as defined in general formula (III).
[0232] Option 3
[0233] The method for preparing the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0234] The compound represented by general formula (IIA) or its salt undergoes a sulfonylation reaction with the compound represented by general formula (IIB) or its salt to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt;
[0235] in:
[0236] R N is halogen; preferably, R N is Cl;
[0237] Z, R x 、R w 、R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n are as defined in general formula (II).
[0238] Option 4
[0239] The method for preparing the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof disclosed herein comprises the following steps:
[0240] The compound represented by general formula (IIIA) or its salt undergoes a sulfonylation reaction with the compound represented by general formula (IIB) or its salt to obtain the compound represented by general formula (III) or its pharmaceutically acceptable salt;
[0241] in:
[0242] R N is halogen; preferably, R N is Cl;
[0243] Z, R x 、R w 、R 1 、R 5c , G 1 , G 3 and n are as defined in general formula (III).
[0244] In the above synthesis scheme, the reagents providing acidic conditions include but are not limited to hydrogen chloride, a 1,4-dioxane solution of hydrogen chloride, a 1,4-dioxane solution of hydrochloric acid, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, concentrated sulfuric acid, methanesulfonic acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, Me3SiCl and TMSOTf and mixtures thereof, preferably trifluoroacetic acid.
[0245] The reaction in the above steps is preferably carried out in a solvent, and the solvent used includes but is not limited to: pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane and mixtures thereof. DETAILED DESCRIPTION
[0246] The present disclosure is further described below with reference to the following embodiments, but these embodiments are not intended to limit the scope of the present disclosure.
[0247] Example
[0248] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), or deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.
[0249] MS measurements were performed using an Agilent 1200 / 1290DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS), a Waters ACQuity UPLC-QD / SQD (manufacturer: Waters, MS model: Waters ACQuity Qda Detector / Waters SQ Detector), and a THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive).
[0250] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC1200VWD and Waters HPLC e2695-2489.
[0251] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.
[0252] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.
[0253] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.
[0254] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).
[0255] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.
[0256] Silica gel column chromatography generally uses Yantai Huanghai 200-300 mesh silica gel as the carrier.
[0257] Average kinase inhibition rate and IC 50 The values were determined using a NovoStar microplate reader (BMG, Germany).
[0258] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui Chemicals, and other companies.
[0259] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.
[0260] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1 L.
[0261] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
[0262] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.
[0263] The hydrogenation reaction is usually carried out by evacuating the chamber and filling it with hydrogen, and the operation is repeated three times.
[0264] A CEM Discover-S 908860 microwave reactor was used for the microwave reaction.
[0265] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0266] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0267] The reaction progress in the examples was monitored by thin layer chromatography (TLC). The developing solvent used in the reaction, the eluent system for column chromatography used to purify the compound, and the developing solvent system for thin layer chromatography included: A: n-hexane / ethyl acetate system, B: dichloromethane / methanol system. The volume ratio of the solvent was adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.
[0268] Example 1
[0269] 3-Methoxy-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 1
[0270] first step
[0271] 5-(Chlorosulfonyl)-2-iodobenzoic acid 1b
[0272] Chlorosulfonic acid (23.50 g, 201.70 mmol, Adamas) was added dropwise to 2-iodobenzoic acid 1a (5 g, 20.10 mmol, Shaoyuan). The reaction mixture was heated to 120°C and stirred for 1 hour. The reaction mixture was cooled to room temperature and then quenched by adding dropwise to crushed ice. The mixture was extracted with dichloromethane (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The desiccant was filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 1b (5.20 g, 74.6% yield). The product was used directly in the next step without purification.
[0273] Step 2
[0274] 2-Iodo-5-(N-(4-methoxybenzyl)-N-methylsulfamoyl)benzoic acid 1c
[0275] Compound 1b (5.20 g, 15 mmol) was dissolved in 50 mL of dichloromethane and the solution was cooled to 0°C. Triethylamine (6.10 g, 60.30 mmol, Sinopharm) and N-methyl-4-methoxybenzylamine (3.40 g, 22.50 mmol, Adamas) were then added sequentially and the reaction was stirred at room temperature for 1 hour. The mixture was quenched by the addition of 50 mL of saturated ammonium chloride solution. The phases were separated, and the aqueous phase was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 1c (9 g, yield: 130.2%). The product was used directly in the next reaction without purification.
[0276] MS m / z(ESI):460.1[M-1].
[0277] Step 3
[0278] 4-Iodo-N-(4-methoxybenzyl)-N-methyl-3-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)benzenesulfonamide 1d
[0279] Compound 1c (2 g, 4.30 mmol), 4-(trifluoromethyl)phenylhydrazine (840 mg, 4.80 mmol, Adamas), and pyridine (1.10 g, 13.90 mmol, Sinopharm) were dissolved in 45 mL of dichloromethane. The reaction solution was cooled to 0°C, and phosphorus oxychloride (665 mg, 4.30 mmol, Adamas) was slowly added dropwise. The reaction was stirred at 0°C for 30 minutes. The reaction was quenched by the addition of 50 mL of saturated sodium bicarbonate solution. The layers were separated, and the aqueous phase was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System A to obtain the target compound 1d (960 mg, 35.7% yield).
[0280] MS m / z(ESI):618.0[M-1].
[0281] Step 4
[0282] 3-Hydroxy-N-(4-methoxybenzyl)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 1e
[0283] Under a nitrogen atmosphere, compound 1d (200 mg, 0.32 mmol), cuprous iodide (7 mg, 0.04 mmol, Alfa), L-proline (8 mg, 0.07 mmol, Adamas), and potassium carbonate (90 mg, 0.65 mmol, Sinopharm) were dissolved in 2 mL of dimethyl sulfoxide and stirred at room temperature for 1 hour. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (30 mL × 2) and saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 1e (147 mg, 93.7% yield). The product was used directly in the next reaction without purification.
[0284] MS m / z (ESI): 492.1 [M+1].
[0285] Step 5
[0286] 3-Methoxy-N-(4-methoxybenzyl)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 1f
[0287] Compound 1e (147 mg, 0.3 mmol) was dissolved in 5 mL of acetone, and cesium carbonate (100 mg, 0.31 mmol, Adamas) and iodomethane (35 mg, 0.25 mmol, Adamas) were added sequentially. The mixture was heated and stirred at 60°C for 30 minutes. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 1f (150 mg, 98.6% yield). The product was used directly in the next reaction without further purification.
[0288] MS m / z (ESI): 506.1 [M+1].
[0289] Step 6
[0290] 3-Methoxy-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 1
[0291] Compound 1f (150 mg, 0.29 mmol) was dissolved in 5 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. The reaction was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the target compound 1 (100 mg, yield: 87.4%).
[0292] MS m / z (ESI): 386.2 [M+1].
[0293] 1H NMR (500MHz, CDCl3): δ8.36(s,1H),7.94-7.92(d,1H),7.86-7.79(m,5H),4.22(s,3H),2.72-2.71(d,3H).
[0294] Example 2
[0295] 3-Isopropoxy-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 2
[0296] first step
[0297] 5-Bromo-3-isopropoxy-1H-indazole 2b
[0298] 5-Bromo-1H-indazol-3-ol 2a (200 mg, 0.94 mmol, Adamas) was dissolved in toluene (10 mL), and isopropyl alcohol (85 mg, 1.38 mmol, Shaoyuan) and (triphenylphosphine)acetonitrile (566 mg, 1.89 mmol, Shaoyuan) were added. The reaction mixture was heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to room temperature and then quenched by adding it dropwise to crushed ice. The mixture was extracted with dichloromethane (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System A to obtain the target compound 2b (95 mg, 39.7% yield).
[0299] MS m / z (ESI): 256.0 [M+1].
[0300] Step 2
[0301] 5-Bromo-3-isopropoxy-1-(4-(trifluoromethyl)phenyl)-1H-indazole 2c
[0302] Under an oxygen atmosphere, compound 2b (95 mg, 0.37 mmol), 4-(trifluoromethyl)phenylboronic acid (212 mg, 1.11 mmol), copper acetate (102 mg, 0.56 mmol), bipyridine (88 mg, 0.56 mmol), and sodium carbonate (119 mg, 1.11 mmol, Sinopharm) were dissolved in 1,2-dichloroethane (10 mL) and stirred at 60°C for 12 hours. After cooling to room temperature, 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL x 2) and saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 2c (30 mg, yield: 20.2%).
[0303] MS m / z (ESI): 401.0 [M+1].
[0304] Step 3
[0305] 3-Isopropoxy-5-((4-methoxybenzyl)thio)-1-(4-(trifluoromethyl)phenyl)-1H-indazole 2d
[0306] Compound 2c (30 mg, 0.08 mmol), (4-methoxyphenyl)methanethiol (18 mg, 0.12 mmol, Sinopharm), tris(dibenzylideneacetone)dipalladium (7 mg, 0.01 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (9 mg, 0.02 mmol), and diisopropylethylamine (30 mg, 0.23 mmol) were dissolved in dioxane (5 mL). Under a nitrogen atmosphere, the mixture was heated to 120°C and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 2d (30 mg, 84.5% yield).
[0307] MS m / z (ESI): 473.3 [M+1].
[0308] Step 4
[0309] 3-Isopropoxy-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonyl chloride 2e
[0310] Compound 2d (40 mg, 0.09 mmol) was dissolved in 8 mL of a mixture of glacial acetic acid and water (V / V = 3:1). N-chlorosuccinimide (68 mg, 0.51 mmol) was added at 0°C, and the mixture was warmed to room temperature and stirred for 4 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 2e (35 mg, yield: 98.7%). The product was used directly in the next reaction without purification.
[0311] Step 5
[0312] 3-Isopropoxy-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 2
[0313] Compound 2e (35 mg, 0.08 mmol) was dissolved in dichloromethane (5 mL), and ethanolic methylamine (48 mg, 0.52 mmol, 30-35% in ethanol) was added. The mixture was stirred at room temperature for 30 minutes. The filtrate was concentrated, and the residue was purified by silica gel column chromatography using eluent System B to obtain the title compound 2 (10 mg, 28.9% yield).
[0314] MS m / z (ESI): 414.3 [M+1].
[0315] 1 H NMR (500MHz, CDCl3): δ8.37(s,1H),7.92-7.90(d,1H),7.85-7.83(d,1H),7 .81-7.78(m,4H),5.29-5.26(m,1H),2.72-2.71(d,3H),1.54-1.53(m,6H).
[0316] Example 3
[0317] 3-Methoxy-N-methyl-1-(4-(trifluoromethyl)benzyl)-1H-indazole-5-sulfonamide
[0318] first step
[0319] 5-Bromo-1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-ol 3a
[0320] Compound 2a (500 mg, 2.29 mmol) was dissolved in water (10 mL), and sodium hydroxide (105 mg, 2.58 mmol, Shaoyuan) was added. The mixture was stirred at 40°C for 10 minutes. 1-(Chloromethyl)-4-(trifluoromethyl)benzene (460 mg, 2.41 mmol, Shaoyuan) was added, and the reaction mixture was heated to 70°C and stirred for 12 hours. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 3a (720 mg, yield: 82.7%). The product was used directly in the next reaction without purification.
[0321] MS m / z (ESI): 372.9 [M+1].
[0322] Step 2
[0323] 5-Bromo-3-methoxy-1-(4-(trifluoromethyl)benzyl)-1H-indazole 3b
[0324] Compound 3a (200 mg, 0.54 mmol) was dissolved in acetone (10 mL), and iodomethane (114 mg, 0.80 mmol) and cesium carbonate (176 mg, 0.54 mmol) were added, and stirred at 60°C for 30 minutes. After cooling to room temperature, 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 3b (134 mg, yield: 64.6%).
[0325] MS m / z (ESI): 387.0 [M+1].
[0326] Step 3
[0327] 3-Methoxy-5-((4-methoxybenzyl)thio)-1-(4-(trifluoromethyl)benzyl)-1H-indazole 3c
[0328] Compound 3b (134 mg, 0.35 mmol), (4-methoxyphenyl)methanethiol (81 mg, 0.53 mmol, Sinopharm), tris(dibenzylideneacetone)dipalladium (32 mg, 0.035 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (41 mg, 0.071 mmol), and diisopropylethylamine (135 mg, 1.1 mmol) were dissolved in dioxane (5 mL). Under a nitrogen atmosphere, the mixture was heated to 120°C and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 3c (150 mg, 94.1% yield).
[0329] MS m / z (ESI): 459.4 [M+1].
[0330] Step 4
[0331] 3-Methoxy-1-(4-(trifluoromethyl)benzyl)-1H-indazole-5-sulfonyl chloride 3d
[0332] Compound 3c (80 mg, 0.17 mmol) was dissolved in 8 mL of a mixture of glacial acetic acid and water (V / V = 3:1). N-chlorosuccinimide (140 mg, 0.98 mmol) was added at 0°C and the reaction was stirred at room temperature for 4 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 3d (70 mg, yield: 99.1%). The product was used directly in the next reaction without purification.
[0333] MS m / z (ESI): 405.1 [M+1].
[0334] Step 5
[0335] 3-Methoxy-N-methyl-1-(4-(trifluoromethyl)benzyl)-1H-indazole-5-sulfonamide
[0336] Compound 3d (70 mg, 0.17 mmol) was dissolved in dichloromethane (5 mL), and ethanolic methylamine (162 mg, 1.67 mmol, 30-35% in ethanol) was added. The mixture was stirred at room temperature for 30 minutes. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the title compound 3 (20 mg, 29.0% yield).
[0337] MS m / z (ESI): 400.3 [M+1].
[0338] 1 H NMR (500MHz, CDCl3): δ8.30(s,1H),7.81-7.78(m,1H),7.60-7.59(m,2H),7.32-7.26(m,3H),5.49(s,2H),4.13(s,3H),2.68-2.67(d,3H).
[0339] Example 4
[0340] 3-Methoxy-N,N-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide
[0341] first step
[0342] 2-Iodo-5-(N-methylsulfamoyl)benzoic acid 4a
[0343] Compound 1b (2.8 g, 8.1 mmol) was dissolved in 30 mL of dichloromethane. The solution was cooled to 0°C, followed by the addition of triethylamine (4.1 g, 40.5 mmol, Sinopharm) and methylamine hydrochloride (820 mg, 12.1 mmol, Sinopharm). The mixture was warmed to room temperature and stirred at room temperature for 1 hour. The mixture was quenched by the addition of 50 mL of saturated ammonium chloride solution. The phases were separated, and the aqueous phase was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 4a (980 mg, yield: 35.5%). The product was used directly in the next reaction without further purification.
[0344] MS m / z(ESI):340.1[M-1].
[0345] Step 2
[0346] 4-Iodo-N-methyl-3-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)benzenesulfonamide 4b
[0347] Compound 4a (200 mg, 0.59 mmol), 4-(trifluoromethyl)phenylhydrazine (115 mg, 0.65 mmol), and pyridine (140 mg, 1.77 mmol, Chinese medicine) were dissolved in 4 mL of dichloromethane and cooled to 0°C. Phosphorus oxychloride (90 mg, 0.59 mmol) was slowly added dropwise, and the mixture was stirred at 0°C for 30 minutes. The reaction was quenched by the addition of 10 mL of saturated sodium bicarbonate solution. The layers were separated, and the aqueous phase was extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System A to obtain the target compound 4b (230 mg, yield: 78.6%).
[0348] MS m / z(ESI):498.0[M-1].
[0349] Step 3
[0350] 3-Hydroxy-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 4c
[0351] Under a nitrogen atmosphere, compound 4b (230 mg, 0.46 mmol), cuprous iodide (9 mg, 0.05 mmol, Alfa), L-proline (11 mg, 0.09 mmol), and potassium carbonate (130 mg, 0.94 mmol, Sinopharm) were dissolved in 3 mL of dimethyl sulfoxide and stirred at room temperature for 1 hour. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (30 mL × 2) and saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 4c (185 mg, yield: 108.0%). The product was used directly in the next reaction without purification.
[0352] MS m / z(ESI):370.1[M-1].
[0353] Step 4
[0354] 3-Methoxy-N,N-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide
[0355] Compound 4c (185 mg, 0.49 mmol) was dissolved in 5 mL of acetone, and cesium carbonate (325 mg, 1.0 mmol) and iodomethane (142 mg, 1.0 mmol) were added sequentially. The reaction mixture was heated and stirred at 60°C for 30 minutes. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System B to obtain the target compound 4 (25 mg, yield: 12.5%).
[0356] MS m / z (ESI): 400.3 [M+1].
[0357] 1 H NMR (500MHz, CDCl3): δ8.27(s,1H),7.87-7.80(m,6H),4.23(s,3H),2.77(s,6H).
[0358] Example 5
[0359] 1-Benzyl-3-methoxy-N-methyl-1H-indazole-5-sulfonamide
[0360] first step
[0361] 1-Benzyl-5-bromo-1H-indazol-3-ol 5a
[0362] Compound 2a (500 mg, 2.31 mmol) was dissolved in water (10 mL), and sodium hydroxide (105 mg, 2.59 mmol, Shaoyuan) was added. The mixture was stirred at 40°C for 10 minutes. Benzyl chloride (298 mg, 2.39 mmol, Shaoyuan) was added, and the reaction mixture was heated to 70°C and stirred for 12 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 5a (600 mg, 84.3% yield). The product was used directly in the next step without further purification.
[0363] MS m / z (ESI): 305.1 [M+1].
[0364] Step 2
[0365] 1-Benzyl-5-bromo-3-methoxy-1H-indazole 5b
[0366] Compound 5a (200 mg, 0.66 mmol) was dissolved in acetone (10 mL), and iodomethane (131 mg, 0.92 mmol) and cesium carbonate (215 mg, 0.66 mmol) were added. The reaction was stirred at 60°C for 30 minutes. After cooling to room temperature, 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 5b (105 mg, yield: 50.2%).
[0367] MS m / z (ESI): 319.1 [M+1].
[0368] Step 3
[0369] 1-Benzyl-3-methoxy-5-((4-methoxybenzyl)thio)-1H-indazole 5c
[0370] Compound 5b (105 mg, 0.33 mmol), (4-methoxyphenyl)methanethiol (77 mg, 0.50 mmol, Sinopharm), tris(dibenzylideneacetone)dipalladium (31 mg, 0.034 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (39 mg, 0.067 mmol), and diisopropylethylamine (129 mg, 1.0 mmol) were dissolved in dioxane (5 mL). Under a nitrogen atmosphere, the mixture was heated to 120°C and stirred for 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 5c (125 mg, 96.7% yield).
[0371] MS m / z(ESI):391.4[M-1].
[0372] Step 4
[0373] 1-Benzyl-3-methoxy-1H-indazole-5-sulfonyl chloride 5d
[0374] Compound 5c (50 mg, 0.13 mmol) was dissolved in 8 mL of a mixture of glacial acetic acid and water (V / V = 3:1). N-chlorosuccinimide (102 mg, 0.76 mmol) was added at 0°C and the reaction was stirred at room temperature for 4 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 5d (40 mg, yield: 92.8%). The product was used directly in the next reaction without purification.
[0375] Step 5
[0376] 1-Benzyl-3-methoxy-N-methyl-1H-indazole-5-sulfonamide
[0377] Compound 5d (40 mg, 0.12 mmol) was dissolved in dichloromethane (5 mL), and ethanolic methylamine (111 mg, 1.21 mmol, 30-35% in ethanol) was added. The mixture was stirred at room temperature for 30 minutes. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the title compound 5 (10 mg, 25.4% yield).
[0378] MS m / z (ESI): 332.3 [M+1].
[0379] 1H NMR (500MHz, CDCl3): δ8.31(s,1H),7.78-7.76(m,1H),7.30-7.20(m,6H),5.49(s,2H),4.13(s,3H),2.68-2.67(d,3H).
[0380] Example 6
[0381] 3-Isopropyl-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 6
[0382] first step
[0383] 5-Bromo-3-isopropyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole 6b
[0384] Under an oxygen atmosphere, 5-bromo-3-isopropyl-1H-indazole 6a (300 mg, 1.31 mmol, Shaoyuan), 4-(trifluoromethyl)phenylboronic acid (715 mg, 3.81 mmol), copper acetate (342 mg, 1.9 mmol), bipyridine (294 mg, 1.88 mmol), and sodium carbonate (399 mg, 3.8 mmol, Sinopharm) were dissolved in 1,2-dichloroethane (10 mL) and stirred at 60°C for 12 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL x 2) and saturated sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System A to obtain the target compound 6b (361 mg, 75.1% yield).
[0385] MS m / z (ESI): 383.1 [M+1].
[0386] Step 2
[0387] 3-Isopropyl-5-((4-methoxybenzyl)thio)-1-(4-(trifluoromethyl)phenyl)-1H-indazole 6c
[0388] Compound 6b (361 mg, 0.94 mmol), (4-methoxyphenyl)methanethiol (218 mg, 1.42 mmol, Sinopharm), tris(dibenzylideneacetone)dipalladium (87 mg, 0.095 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (110 mg, 0.19 mmol), and diisopropylethylamine (366 mg, 2.79 mmol) were dissolved in dioxane (10 mL) and stirred at 120°C under a nitrogen atmosphere for 5 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 6c (430 mg, 99.9% yield).
[0389] MS m / z (ESI): 457.5 [M+1].
[0390] Step 3
[0391] 3-Isopropyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonyl chloride 6d
[0392] Compound 6c (100 mg, 0.22 mmol) was dissolved in 8 mL of a mixture of glacial acetic acid and water (V / V = 3:1). N-chlorosuccinimide (176 mg, 1.31 mmol) was added at 0°C and stirred at room temperature for 4 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 6d (80 mg, yield: 90.1%). The product was used directly in the next reaction without purification.
[0393] MS m / z (ESI): 403.1 [M+1].
[0394] Step 4
[0395] 3-Isopropyl-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 6
[0396] Compound 6d (80 mg, 0.20 mmol) was dissolved in dichloromethane (5 mL), and ethanolic methylamine (186 mg, 2.01 mmol, 30-35% in ethanol) was added. The mixture was stirred at room temperature for 30 minutes. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the title compound 6 (15 mg, 19.0% yield).
[0397] MS m / z (ESI): 398.4 [M+1].
[0398] 1H NMR (500MHz, CDCl3): δ8.43(s,1H),7.91-7.83(m,6H),3.55-3.52(m,1H),2.73-2.72(d,3H),1.59-1.54(m,6H).
[0399] Example 7
[0400] N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 7
[0401] first step
[0402] 5-Bromo-1-(4-(trifluoromethyl)phenyl)-1H-indazole 7b
[0403] 5-Bromo-2-fluorobenzaldehyde 7a (1 g, 4.88 mmol), 4-(trifluoromethyl)phenylhydrazine (867 mg, 4.88 mmol), and cesium carbonate (3.2 g, 9.87 mmol) were dissolved in N,N-dimethylformamide (30 mL) and stirred at 120°C for 2 hours. After cooling to room temperature, 30 mL of ethyl acetate was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude target compound 7b (200 mg, yield: 11.9%). The product was used directly in the next reaction without purification.
[0404] MS m / z (ESI): 343.1 [M+1].
[0405] Step 2
[0406] 5-((4-methoxybenzyl)thio)-1-(4-(trifluoromethyl)phenyl)-1H-indazole 7c
[0407] Compound 7b (100 mg, 0.29 mmol), (4-methoxyphenyl)methanethiol (59 mg, 0.38 mmol, Sinopharm), tris(dibenzylideneacetone)dipalladium (27 mg, 0.029 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (34 mg, 0.059 mmol), and diisopropylethylamine (76 mg, 0.59 mmol) were dissolved in dioxane (5 mL). Under a nitrogen atmosphere, the mixture was heated to 120°C and stirred for 5 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the target compound 7c (100 mg, 82.3% yield).
[0408] MS m / z (ESI): 415.1 [M+1].
[0409] Step 3
[0410] 1-(4-(Trifluoromethyl)phenyl)-1H-indazole-5-sulfonyl chloride 7d
[0411] Compound 7c (100 mg, 0.24 mmol) was dissolved in 8 mL of a mixture of glacial acetic acid and water (V / V = 3:1). N-chlorosuccinimide (129 mg, 1.01 mmol) was added at 0°C, the mixture was warmed to room temperature, and the reaction was stirred at room temperature for 4 hours. 30 mL of dichloromethane was added for dissolution. The organic phase was washed with water (20 mL × 2) and saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 7d (80 mg, yield: 91.9%). The product was used directly in the next reaction without purification.
[0412] MS m / z (ESI): 361.1 [M+1].
[0413] Step 4
[0414] N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 7
[0415] Compound 7d (80 mg, 0.22 mmol) was dissolved in dichloromethane (5 mL), and ethanolic methylamine (207 mg, 2.22 mmol, 30-35% in ethanol) was added. The mixture was stirred at room temperature for 30 minutes. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the title compound 7 (25 mg, 31.7% yield).
[0416] MS m / z (ESI): 356.1 [M+1].
[0417] 1 H NMR (500MHz, CD3OD): δ8.53-8.52(d,1H), δ8.46(s,1H), δ8.10-7.94(m,6H), 2.57-2.56(d,3H).
[0418] Example 8
[0419] 3-(Dimethylamino)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 8
[0420] first step
[0421] 3-Cyano-4-fluoro-N-(4-methoxybenzyl)-N-methylbenzenesulfonamide 8b
[0422] 3-Cyano-4-fluorobenzenesulfonyl chloride 8a (1 g, 4.5 mmol, Bidler) was dissolved in 15 mL of dichloromethane. The solution was cooled to 0°C, followed by the addition of N,N-diisopropylethylamine (1.20 g, 9.10 mmol, Adamas) and N-methyl-4-methoxybenzylamine (690 mg, 4.50 mmol). The reaction was stirred at room temperature for 1 hour. The mixture was quenched by the addition of 50 mL of saturated ammonium chloride solution. The layers were separated, and the aqueous phase was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 8b (1.20 g, 78.9% yield). The product was used directly in the next reaction without further purification.
[0423] MS m / z(ESI):333.2[M-1].
[0424] Step 2
[0425] 3-Amino-N-(4-methoxybenzyl)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 8c
[0426] Under a nitrogen atmosphere, 4-(Trifluoromethyl)phenylhydrazine (475 mg, 2.70 mmol) was dissolved in 1 mL of diethylene glycol dimethyl ether. Potassium tert-butoxide (135 mg, 1.20 mmol, Shaoyuan) was added and stirred at room temperature for 5 minutes. Compound 8b (300 mg, 0.90 mmol) was then added. The mixture was sealed and heated to 130°C with stirring for 1 hour. After cooling to room temperature, 50 mL of dichloromethane was added for dissolution. The organic phase was washed with water (50 mL × 2) and saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System A to obtain the target compound 8c (214 mg, 48.2% yield).
[0427] MS m / z (ESI): 491.1 [M+1].
[0428] Step 3
[0429] 3-(Dimethylamino)-N-(4-methoxybenzyl)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 8d
[0430] Compound 8c (100 mg, 0.20 mmol) was dissolved in 2 mL of N,N-dimethylformamide and cooled to 0°C. Sodium hydride (7 mg, 0.18 mmol, Sinopharm) was added and stirred for 10 minutes. Iodomethane (43 mg, 0.30 mmol) was added, the reaction was warmed to room temperature, and stirred for 12 hours. The mixture was quenched by the addition of 10 mL of saturated ammonium chloride solution. The layers were separated, and the aqueous phase was extracted with dichloromethane (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 8d (102 mg, yield: 98.3%). The product was used directly in the next reaction without further purification.
[0431] MS m / z (ESI): 519.3 [M+1].
[0432] Step 4
[0433] 3-(Dimethylamino)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 8
[0434] Compound 8d (102 mg, 0.2 mmol) was dissolved in 5 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. The reaction was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the target compound 8 (5 mg, yield: 6.4%).
[0435] MS m / z (ESI): 399.0 [M+1].
[0436] 1 H NMR (500MHz, CDCl3): δ8.48(s,1H),8.01-7.99(d,2H),7.83-7.82(d,2H),7.67-7.65(d,2H),7.58-7.56(d,2H),3.04(m,6H),2.72-2.71(d,3H).
[0437] Example 9
[0438] N-methyl-3-(methylamino)-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 9
[0439] first step
[0440] 3-Amino-N-(4-methoxybenzyl)-N-methyl-1H-indazole-5-sulfonamide 9a
[0441] Compound 8b (690 mg, 2.06 mmol) was dissolved in 10 mL of ethanol, and hydrazine hydrate (516 mg, 10.30 mmol, Chinese medicine) was added. The reaction was heated to 100°C and stirred for 12 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure to obtain the crude title compound 9a (780 mg, yield: 109.2%), which was used directly in the next reaction without purification.
[0442] MS m / z (ESI): 347.1 [M+1].
[0443] Step 2
[0444] 3-Amino-N-(4-methoxybenzyl)-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 8c
[0445] Compound 9a (780 mg, 2.25 mmol) was dissolved in 8 mL of methanol. Copper acetate (82 mg, 0.45 mmol, Sinopharm) and 4-(trifluoromethyl)phenylboronic acid (470 mg, 2.48 mmol, Shaoyuan) were added. The reaction was stirred under air for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to obtain the title compound 8c (310 mg, 28.1% yield).
[0446] MS m / z (ESI): 491.1 [M+1].
[0447] Step 3
[0448] N-(4-Methoxybenzyl)-N-methyl-3-(methylamino)-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 9b
[0449] Compound 8c (100 mg, 0.2 mmol) was dissolved in 1 mL of methanol. Paraformaldehyde (25 mg, 0.82 mmol, Sinopharm) and sodium methoxide (110 mg, 2.0 mmol, Adamas) were added sequentially. The reaction was heated to 70°C with stirring for 1 hour. The reaction solution was cooled to room temperature, and sodium borohydride (16 mg, 0.41 mmol, Sinopharm) was added. The reaction was heated to 70°C with stirring for 2 hours. The reaction solution was cooled to room temperature and quenched with 5 mL of ice water. The aqueous phase was extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 9b (100 mg, 99.0% yield). The product was used directly in the next step without purification.
[0450] MS m / z (ESI): 505.1 [M+1].
[0451] Step 4
[0452] N-methyl-3-(methylamino)-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 9
[0453] Compound 9b (100 mg, 0.2 mmol) was dissolved in 5 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. The reaction was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the target compound 9 (10 mg, yield: 13.0%).
[0454] MS m / z (ESI): 385.1 [M+1].
[0455] 1 H NMR (500MHz, DMSO-d6): δ8.45(s,1H),8.05-7.99(m,3H),7.87-7.81(m,3H),7.40(s,1H),7.08(s,1H),2.98-2.96(d,3H),2.42(s,3H).
[0456] Example 10
[0457] 3-Amino-N-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole-5-sulfonamide 10
[0458] Compound 8c (100 mg, 0.2 mmol) was dissolved in 5 mL of dichloromethane, and 0.5 mL of trifluoroacetic acid was added. The reaction was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent System B to obtain the target compound 10 (10 mg, yield: 13.2%).
[0459] MS m / z (ESI): 371.0 [M+1].
[0460] 1 H NMR (500MHz, DMSO-d6): δ8.49(s,1H),8.04-8.03(d,1H),7.96-7.95(d,2H), 7.87-7.85(d,2H),7.82-7.80(d,1H),7.40(s,1H),6.43(s,2H),2.43(s,3H).
[0461] Example 11
[0462] 3-Methoxy-1-[4-(trifluoromethyl)phenyl]-1H-indazole-5-sulfonamide 11
[0463] first step
[0464] 2-Iodo-N'-[4-(trifluoromethyl)phenyl]benzohydrazide 11c
[0465] 2-Iodobenzoic acid 11a (50.0 g, 201.60 mmol, Adamas) was dissolved in dichloromethane (1000 mL), and O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (84.3 g, 221.71 mmol) was added. After stirring, (4-(trifluoromethyl)phenyl)hydrazine hydrochloride 11b (45.0 g, 211.67 mmol, Jiangsu Aikon) was added. The mixture was cooled in a water bath, and N,N-diisopropylethylamine (57.3 g, 443.35 mmol, 75.9 mL) was added dropwise. The internal temperature was maintained at about 25°C. The turbid reaction solution gradually clarified. After about 15 minutes, it suddenly precipitated when the addition was almost complete. A large amount of solid was produced, and the internal temperature did not change significantly. 500 mL of dichloromethane was added to ensure smooth stirring. The reaction was stirred at room temperature for 30 minutes. 500 mL of dichloromethane was added to dilute the reaction solution, and 1000 mL of 10% citric acid aqueous solution was added and stirred for 10 minutes. The solid was collected by filtration, and the solid was dissolved in 1200 mL of ethyl acetate, separated and dehydrated, and dried over anhydrous sodium sulfate. After the filtrate was separated, the organic phase was washed with 10% citric acid aqueous solution (1×200 mL) and 10% sodium carbonate aqueous solution (1×500 mL), and dried over anhydrous sodium sulfate. The organic phases were combined to obtain a yellow solid, which was the title compound 11c (120 g, yield: 146.6%). The product was used directly in the next reaction without purification.
[0466] MS m / z (ESI): 406.9 [M+1].
[0467] Step 2
[0468] 1-[4-(Trifluoromethyl)phenyl]-1H-indazol-3-ol 11d
[0469] Dimethyl sulfoxide (600 mL) was added to compound 11c (81.8 g, 210.41 mmol), L-proline (4.67 g, 40.56 mmol), cuprous iodide (38.4 g, 201.62 mmol) and anhydrous potassium carbonate (55.7 g, 403.02 mmol). The mixture was replaced with nitrogen three times and reacted at room temperature for 1 hour. The reaction solution was slowly poured into 3000 mL of ice-water mixture to quench the reaction. The mixture was stirred for 10 minutes and extracted with ethyl acetate (3×1000 mL). The organic phases were combined, washed with sodium chloride aqueous solution (10%) (1×500 mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain 23 g of a crude product. The aqueous phase was adjusted to pH 4-5 with concentrated hydrochloric acid and extracted again with ethyl acetate (2×500 mL). The organic phase was washed with aqueous sodium chloride solution (10%) (1×300 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and 23 g of the crude product was combined and purified by silica gel column chromatography with eluent System A to give the title product 11d (9.6 g, yield: 17.1%).
[0470] MS m / z (ESI): 278.9 [M+1].
[0471] Step 3
[0472] 3-Hydroxy-1-[4-(trifluoromethyl)phenyl]-1H-indazole-5-sulfonyl chloride 11e
[0473] Compound 11d (6.0 g, 21.56 mmol) was dissolved in chloroform (60 mL). Sulfonyl chloride (14.6 g, 108.17 mmol, 8.3 mL) was added dropwise at room temperature. The reaction mixture was allowed to react at 60°C for 1 hour. After cooling to room temperature, the reaction solution was concentrated to remove the solvent, and the residue was added dropwise to 80 mL of ice-water mixture, whereupon a large amount of solid precipitated. After stirring for 10 minutes, the solid was collected by filtration and washed with water (2 x 5 mL). The solid was filtered and completely dissolved in 150 mL of ethyl acetate. The solid was then dried over anhydrous sodium sulfate. After drying, a solid precipitated quickly. 150 mL of tetrahydrofuran was added to aid dissolution. The solution was essentially clear (a small amount of suspended solid remained undissolved). The solution was then filtered through filter paper, washed with tetrahydrofuran (2 x 5 mL), and the filtrate was concentrated and dried to give the title product 11e (7.47 g, 91.9% yield).
[0474] MS m / z (ESI): 376.9 [M+1].
[0475] Step 4
[0476] 3-Hydroxy-N,N-bis[(4-methoxybenzyl]-1-[4-(trifluoromethyl)phenyl]-1H-indazole-5-sulfonamide 11f
[0477] Dissolve bis-(4-methoxybenzyl)-amine (1.75 g, 6.80 mmol, Shaoyuan) in tetrahydrofuran (15 mL) and stir until uniform. Dissolve compound 11e (513 mg, 1.3617 mmol) in tetrahydrofuran (15 mL) and add dropwise to the reaction mixture. After addition, react for 10 minutes. Filter to remove insoluble matter. Add 10 mL of 1M lithium hydroxide aqueous solution and 5 mL of methanol, stir for 1 hour, acidify to pH 5-6 with 10% citric acid aqueous solution, concentrate to remove the organic phase, collect the precipitated solid by filtration, dissolve in tetrahydrofuran, dry over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography with eluent system A to obtain the title product 11f (234 mg, yield: 28.8%).
[0478] MS m / z (ESI): 598.1 [M+1].
[0479] Step 5
[0480] 3-Methoxy-N,N-bis[(4-methoxybenzyl]-1-[4-(trifluoromethyl)phenyl]-1H-indazole-5-sulfonamide11h
[0481] Compound 11f (500 mg, 0.8367 mmol) was dissolved in acetone (15 mL) and stirred evenly. Cesium carbonate (818 mg, 2.511 mmol) and iodomethane (357 mg, 2.515 mmol, 0.157 mL) were added and reacted at room temperature for 1 hour. The reaction solution was concentrated to remove the solvent, and 50 mL of water was added. The mixture was extracted with a mixed solution (20 mL of ethyl acetate + 4 mL of tetrahydrofuran) × 3 times, dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography with eluent system A to obtain the title product 11h (287 mg, yield: 56.1%).
[0482] Step 6
[0483] 3-Methoxy-1-[4-(trifluoromethyl)phenyl]-1H-indazole-5-sulfonamide 11
[0484] Trifluoroacetic acid (1.34 g, 11.7520 mmol, 0.873 mL) was dissolved in dichloromethane (2 mL) and added to compound 11h (287 mg, 0.4692 mmol). The mixture was reacted at room temperature for 3 hours. The reaction solution was concentrated and neutralized to pH 7-8 by adding 20 mL of saturated aqueous sodium bicarbonate solution. The mixture was diluted with 20 mL of water and extracted with a mixed solvent (20 mL of dichloromethane + 2 mL of methanol) × 3 times. The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography with eluent system A to obtain the title product 11 (103 mg, yield: 59.4%).
[0485] MS m / z (ESI): 372.0 [M+1].
[0486] 1 H NMR(500MHz,DMSO-d6)δ8.18(s,1H),8.10(d,J=9.0Hz,1H),8.02(d,J=8.4Hz ,2H),7.97(d,J=9.1Hz,1H),7.92(d,J=8.4Hz,2H),7.43(s,2H),4.17(s,3H).
[0487] Biological evaluation
[0488] Test Example 1: Test of the Inhibitory Effect of the Disclosed Compounds on YAP-TEAD-Mediated Reporter Gene Luc2P Luciferase Activity
[0489] The 8×GTIIC-Luc2P (GenWeiZhi) plasmid was transformed into HEK293 (ATCC, CRL-1573) cells, and the HEK293-8×GTIIC-Luc2P cell line was obtained by antibiotic selection and selection of single clones. HEK293-8×GTIIC-Luc2P cells were cultured at 2×10 4 The cells were seeded at a density of 90 μL / well in a 96-well plate (Beyotime, FCP968) and cultured for 24 hours. The compound was prepared with DMSO and gradient diluted, with the initial concentration of 10 mM, and diluted in 5-fold gradients for a total of 9 concentration points. The blank control and vehicle control were 100% DMSO. Then 5 μL of the gradient diluted compound was taken from each well and added to 95 μL of complete culture medium in each well. After shaking and mixing, 10 μL of the compound diluted with culture medium was taken from each well and added to the 96-well plate containing cells. The final initial concentration of the compound was 10 μM. The wells with only culture medium but no cells were blank controls, and the wells with cells but no compounds were vehicle controls. The DMSO content in the compound wells, blank controls, and vehicle controls was 0.5%. After the cells continued to incubate in the incubator for 24 hours, the 96-well plate was removed and 50 μL One Glo was added to each well. TM Luciferase (Promega, E6120) was shaken at room temperature for 5 min and the luminescence signal was read using a microplate reader (PerkinElmer Victor3). The inhibition rate of each concentration of the compound was calculated using the following formula. The IC value of the inhibitory activity of the compound was calculated based on the inhibition rate using Graphpad Prism software. 50 The maximum inhibition rate is the maximum inhibition rate. 溶媒对照 -RLU 化合物孔 ) / (RLU 溶媒对照 -RLU 空白对照)×100%
[0490] Table 1 Inhibitory effect of the disclosed compounds on the YAP / TAZ-TEAD-mediated reporter gene Luc2P luciferase activity
[0491] Conclusion: The disclosed compounds have a significant inhibitory effect on the activity of the YAP / TAZ-TEAD-mediated reporter gene Luc2P luciferase.
[0492] Test Example 2 Inhibitory effect of the disclosed compounds on the proliferation of NCI-H226 cells
[0493] On the first day of the experiment, well-grown NCI-H226 (ATCC, CRL-5826) cells reaching 70%-80% confluence were digested and resuspended in RPMI (Hyclone, SH30809.01) supplemented with 10% FBS to the desired cell density. 135 μL of the cell suspension was added to each well of a 96-well plate (Corning, 3903) at a density of 1,000 cells / well. The plate was incubated in a 37°C, 5% CO2 incubator for 24 hours. On the second day, a 20 mM DMSO-dissolved test compound was diluted with DMSO to a starting concentration of 2 mM, followed by a 5-fold serial dilution to a total of nine concentration points. DMSO was then added to the control wells. The serial dilutions were then further diluted 20-fold with culture medium. 15 μL of the test compound diluted with culture medium was added to each well of the plate to a final concentration of 10 μM starting at the 10 mM concentration and then diluted to the 9 concentration points of the 5-fold serial dilution. The wells containing 0.5% DMSO were set as vehicle control wells, and the wells containing only culture medium and 0.5% DMSO were set as blank control wells. Each concentration of compound and control wells were set in duplicate, and the final DMSO concentration in each well was 0.5%. The cell plate was placed in a 37°C, 5% CO2 incubator for 6 days. On the eighth day, the 96-well cell culture plate was removed and 50 μL of luminescent cell activity detection reagent ( Luminescent Cell Viability Assay) (Promega, G7573) was placed in the dark at room temperature for 10 minutes and then placed on a microplate reader VICTOR3 to read the luminescent signal value.
[0494] The inhibition rate was calculated using the following formula: Inhibition rate = [RLU (vehicle control well) - RLU (test compound)] / [RLU (vehicle control well) - RLU (blank control well)] × 100%. Graphpad Prism software was used to draw inhibition curves based on the compound concentrations and the corresponding inhibition rates, and the IC of the compound was calculated. 50 value.
[0495] Table 2 Inhibitory effect of the disclosed compounds on proliferation of NCI-H226 cells
[0496] Conclusion: The disclosed compounds have a good inhibitory effect on NCI-H226 cells.
[0497] Test Example 3 Pharmacokinetic Evaluation of the Disclosed Compounds in Rats
[0498] 1. Abstract
[0499] The concentration of the compound of Example 1 in the rat plasma at different time points after oral administration of the compound of Example 1 was determined using LC / MS / MS. The pharmacokinetic behavior of the disclosed compound in rats was studied and its pharmacokinetic characteristics were evaluated.
[0500] 2. Experimental plan
[0501] 2.1 Experimental Drugs
[0502] Example 1 Compound.
[0503] 2.2 Experimental Animals
[0504] Four SD rats, half male and half female, were provided by Weitonglihua Experimental Animal Technology Co., Ltd., animal production license number: SCXK (Zhejiang) 2019-0001.
[0505] 2.3 Drug preparation
[0506] A certain amount of the compound of Example 1 was weighed, and 5% DMSO + 20% PEG400 + 70% (10% TPGS) + 5% (1% HPMCK100LV) was added to form a 0.5 mg / mL clear solution.
[0507] 2.4 Drug Administration
[0508] The compound of Example 1 was administered orally at a dose of 5 mg / kg in a volume of 10 mL / kg.
[0509] 3. Operation
[0510] Rats were orally administered the compound of Example 1. 0.1 mL of blood was collected from the orbital cavity at 0.25, 0.5, 1, 2, 4, 6, 8, 11, and 24 hours after administration. The blood was placed in an EDTA-K2 anticoagulant tube and centrifuged at 10,000 rpm for 1 minute at 4°C. Plasma was separated within 1 hour and stored at -20°C. The blood collection and centrifugation process was performed in an ice bath.
[0511] The content of Example 1 compound in rat plasma after administration of Example 1 compound was determined: 25 μL of rat plasma at each time point after administration was added with 200 μL of ACN (containing tolbutamide 100 ng / mL), vortexed for 5 min, centrifuged for 15 min (3700 rpm), 100 μL of the supernatant was added with 50 μL of water and mixed for 5 min, and 2 μL was taken for LC / MS / MS analysis.
[0512] 4. Pharmacokinetic parameter results
[0513] Table 3 Pharmacokinetic parameters of the disclosed compounds
[0514] Conclusion: The disclosed compounds have good pharmacokinetic and absorption activity in rats.
[0515] Test Example 4 Pharmacokinetic Evaluation of the Disclosed Compounds in Beagle Dogs
[0516] 1. Abstract
[0517] Beagle dogs were used as test animals, and the concentration of Example 1 in the plasma of Beagle dogs at different time points after oral administration of Example 1 was determined by LC / MS / MS. The pharmacokinetic behavior of the disclosed compound in Beagle dogs was studied and its pharmacokinetic characteristics were evaluated.
[0518] 2. Experimental plan
[0519] 2.1 Experimental Drugs
[0520] Example 1 Compound.
[0521] 2.2 Experimental Animals
[0522] Four Beagle dogs, half male and half female, were provided by Tianjin Kangwens Biotechnology Co., Ltd.
[0523] 2.3 Drug preparation
[0524] A certain amount of the compound of Example 1 was weighed and added with 5% DMSO + 30% PG + 30% PEG400 + 35% saline to form a clear solution of 0.4 mg / mL.
[0525] 2.4 Drug Administration
[0526] The compound of Example 1 was administered orally at a dose of 2 mg / kg in a volume of 5 mL / kg.
[0527] 3. Operation
[0528] Beagle dogs were fasted overnight and gavage-administered the compound of Example 1. Blood (0.5 mL) was collected from the forelimb vein at 0 h before administration and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 11 h, and 24 h after administration. The blood was placed in an EDTA-K2 anticoagulant tube and centrifuged at 10,000 rpm for 2 minutes (4°C). Plasma was separated within 1 hour and stored at -80°C. Food was administered 3 h after administration.
[0529] The content of Example 1 in Beagle dog plasma after administration of the compound of Example 1 was determined by taking 50 μL of Beagle dog plasma at various times after administration, adding 25 μL of camptothecin (1 μg / mL) and 450 μL of acetonitrile, vortexing, and centrifuging for 10 min (3700 rpm). 0.5 μL of the supernatant was collected for LC / MS / MS analysis.
[0530] 4. Pharmacokinetic parameter results
[0531] Table 4 Pharmacokinetic parameters of the disclosed compounds
[0532] Conclusion: The disclosed compounds have good pharmacokinetic and absorption activity in Beagle dogs.
Claims
1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: in: Z is O or NH; Ring A is an aryl group or a heteroaryl group; R is an alkyl group or R w R x N, the alkyl group is optionally substituted with one or more substituents selected from the group consisting of a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a halogenated alkoxy group, a cyano group, an amino group, and a hydroxyl group; R 1 Selected from hydrogen atoms, deuterium atoms, halogens, alkyl groups, R v O and R y R z N, the alkyl group is optionally substituted with one or more substituents selected from the group consisting of a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a halogenated alkoxy group, a cyano group, an amino group, and a hydroxyl group; R w 、R x 、R y and R z are the same or different and are each independently selected from a hydrogen atom, a deuterium atom and an alkyl group, wherein the alkyl group is optionally substituted with one or more substituents selected from a deuterium atom, a halogen, an alkoxy group, a deuterated alkoxy group, a haloalkoxy group, a cyano group, an amino group and a hydroxyl group; R v is selected from alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from deuterium, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, and a hydroxyalkyl group; R 2 、R 3 and R 4 are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n1 R n2 、-C(O)NR n3 R n4 、-C(O)R a1 、-C(O)OR a2 、-OR a3 、-S(O) t1 R a4 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; Each R 5 are the same or different and are each independently selected from a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently selected from deuterium atoms, halogen, oxo, alkyl, deuterated alkane substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R n1 、R n2 、R n3 、R n4 、R n5 、R n6 、R n7 and R n8 is the same or different at each occurrence and is independently selected from the group consisting of a hydrogen atom, a deuterium atom, an alkyl group, a deuterated alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group; or R n1 and R n2 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, R n3 and R n4 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, R n5 and R n6 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group or R n7 and R n8 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, wherein each of the heterocyclic groups is independently optionally substituted by one or more substituents selected from the group consisting of a deuterium atom, a halogen, an oxo group, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, a deuterated alkoxy group, a haloalkoxy group, a cyano group, an amino group, a nitro group, a hydroxyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; R a1 、R a2 、R a3 、R a4 、R a5 、R a6 、R a7 and R a8 are the same or different at each occurrence and are each independently selected from the group consisting of hydrogen, deuterium, alkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of deuterium, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; t1 is 0, 1, or 2; t2 is 0, 1, or 2; m is 0, 1, 2, 3, 4, 5 or 6; n is 0, 1, or 2; The condition is, i) When R is R w R x When N and n is 1, Not for ii) When R is methyl and n is 0, R 1 Not for 2. The compound of general formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R is R w R x N, R w and R x As defined in claim 1.
3. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, which is a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof: in: G 0 is a nitrogen atom or CR 5a ; G 1 is a nitrogen atom or CR 5b ; G 2 is a nitrogen atom or CR 5d ; G 3 is a nitrogen atom or CR 5e ; R 5a Selected from hydrogen atom, deuterium atom, F, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; R 5c Selected from hydrogen atom, deuterium atom, Cl, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; R 5b 、R 5d and R 5e are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, an alkenyl group, an alkynyl group, a nitro group, a cyano group, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; Among them, Z, R w 、R x 、R 1 、R 2 、R 3 、R 4 、R a 、R b 、R n5 、R n6 、R n7 、R n8 、R a5 、R a6 、R a7 、R a8 , t2 and n are as defined in claim 1.
4. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 3, which is a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof: Among them, Z, R w 、R x 、R 1 , G 1 , G 3 、R 5c and n is as defined in claim 3; preferably, Z is O.
5. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 1 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy and R y R z N, R y and R z As defined in claim 1; preferably, R y and R z The same or different, and each independently a hydrogen atom or a C 1-6 alkyl. 6 . The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 , wherein n is 0 or 1.
7. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 3 to 6, wherein G 1 and G 3 All are CH.
8. The compound of any one of the general formula (I) according to claim 3 or a pharmaceutically acceptable salt thereof, wherein R 5c A hydrogen atom or C 1-6 Halogenated alkyl.
9. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein R w A hydrogen atom or C 1-6 alkyl.
10. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein R x A hydrogen atom or C 1-6 Alkyl; preferably, R x C 1-6 alkyl.
11. The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, which is selected from the following compounds:
12. A compound represented by general formula (IIa) or a salt thereof: in: R L is an amino protecting group; preferably, R L For PMB; R x , Z, R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n as defined in claim 3.
13. The compound represented by general formula (IIa) or a salt thereof according to claim 12, which is selected from the following compounds:
14. A compound represented by general formula (IIA) or a salt thereof: in: R N is halogen; preferably, R N is Cl; R 5c Selected from deuterium atoms, Cl, Br, I, alkyl, alkenyl, alkynyl, nitro, cyano, -NR n5 R n6 、-C(O)NR n7 R n8 、-C(O)R a5 、-C(O)OR a6 、-OR a7 、-S(O) t2 R a8 , cycloalkyl, heterocyclic, aryl and heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium atoms, halogen, oxo, alkyl, deuterated alkyl, haloalkyl, alkoxy, deuterated alkoxy, haloalkoxy, nitro, cyano, amino, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; Z, R 1 、R 2 、R 3 、R 4 、R a 、R b , G 0 , G 1 , G 2 , G 3 、R n5 、R n6 、R n7 、R n8 、R a5 、R a6 、R a7 、R a8 , t2 and n are as defined in claim 3.
15. A compound selected from the following structures:
16. A method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps: The compound represented by general formula (IIa) or its salt is subjected to a deprotection reaction to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt; in: R L is an amino protecting group; preferably, R L For PMB; R w is a hydrogen atom; R x , Z, R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n as defined in claim 3.
17. A method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps: The compound represented by general formula (IIA) or its salt undergoes a sulfonylation reaction with the compound represented by general formula (IIB) or its salt to obtain the compound represented by general formula (II) or its pharmaceutically acceptable salt; in: R N is halogen; preferably, R N is Cl; Z, R x 、R w 、R 1 、R 2 、R 3 、R 4 、R 5c 、R a 、R b , G 0 , G 1 , G 2 , G 3 and n as defined in claim 3.
18. A pharmaceutical composition comprising a compound represented by general formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
19. Use of the compound represented by general formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 18 in the preparation of a TEAD inhibitor drug.
20. Use of a compound of formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 18, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by YAP / TAZ-TEAD interaction.
21. Use of the compound represented by the general formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 18 in the preparation of a medicament for treating and / or preventing cancer, fibrosis, polycystic kidney disease and cardiovascular disease; the fibrosis is preferably liver fibrosis; the cancer is preferably selected from mesothelioma, schwannoma, leukemia, lymphoma, macroglobulinemia, heavy chain disease, sarcoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, cystadenocarcinoma, medullary carcinoma, bronchial duct cancer, liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, endometrial cancer, testicular cancer, lung cancer, bladder cancer, glioma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioma, acoustic neuroma, schwannoma, neurofibroma, retinoblastoma, melanoma, skin cancer, kidney cancer, nasopharyngeal cancer, stomach cancer, esophageal cancer, head and neck cancer, colorectal cancer, small intestine cancer, gallbladder cancer, pediatric cancer, urothelial carcinoma, ureteral cancer, thyroid cancer, osteoma, neuroblastoma, brain tumor, ependymoma and myeloma.
